#ba_3_2 — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #ba_3_2, aggregated by home.social.
-
#usa #at_least_23_other_countries
#SARS_CoV_2 #COVID19 #COVID #BA_3_2 #BA_3_2_1 #BA_3_2_2
#COVIDISNOTOVER
New COVID variant with immune escape potential confirmed in US, 22 other countries | CIDRAP
https://www.cidrap.umn.edu/covid-19/new-covid-variant-immune-escape-potential-confirmed-us-22-other-countries -
#usa #at_least_23_other_countries
#SARS_CoV_2 #COVID19 #COVID #BA_3_2 #BA_3_2_1 #BA_3_2_2
#COVIDISNOTOVER
New COVID variant with immune escape potential confirmed in US, 22 other countries | CIDRAP
https://www.cidrap.umn.edu/covid-19/new-covid-variant-immune-escape-potential-confirmed-us-22-other-countries -
#usa #at_least_23_other_countries
#SARS_CoV_2 #COVID19 #COVID #BA_3_2 #BA_3_2_1 #BA_3_2_2
#COVIDISNOTOVER
New COVID variant with immune escape potential confirmed in US, 22 other countries | CIDRAP
https://www.cidrap.umn.edu/covid-19/new-covid-variant-immune-escape-potential-confirmed-us-22-other-countries -
#usa #at_least_23_other_countries
#SARS_CoV_2 #COVID19 #COVID #BA_3_2 #BA_3_2_1 #BA_3_2_2
#COVIDISNOTOVER
New COVID variant with immune escape potential confirmed in US, 22 other countries | CIDRAP
https://www.cidrap.umn.edu/covid-19/new-covid-variant-immune-escape-potential-confirmed-us-22-other-countries -
#usa #at_least_23_other_countries
#SARS_CoV_2 #COVID19 #COVID #BA_3_2 #BA_3_2_1 #BA_3_2_2
#COVIDISNOTOVER
New COVID variant with immune escape potential confirmed in US, 22 other countries | CIDRAP
https://www.cidrap.umn.edu/covid-19/new-covid-variant-immune-escape-potential-confirmed-us-22-other-countries -
Here's the latest variant picture for Northern Ireland, to late February.
BA.3.2.* "Cicada" has been dominant at 67%.
XFG.* "Stratus" continued falling to finish at 39%
No samples have been shared from the other home countries since February 9.
-
Here's the latest variant picture for Northern Ireland, to late February.
BA.3.2.* "Cicada" has been dominant at 67%.
XFG.* "Stratus" continued falling to finish at 39%
No samples have been shared from the other home countries since February 9.
-
Here's the latest variant picture for Northern Ireland, to late February.
BA.3.2.* "Cicada" has been dominant at 67%.
XFG.* "Stratus" continued falling to finish at 39%
No samples have been shared from the other home countries since February 9.
-
Here's the latest variant picture for Northern Ireland, to late February.
BA.3.2.* "Cicada" has been dominant at 67%.
XFG.* "Stratus" continued falling to finish at 39%
No samples have been shared from the other home countries since February 9.
-
Here's the latest variant picture for Northern Ireland, to late February.
BA.3.2.* "Cicada" has been dominant at 67%.
XFG.* "Stratus" continued falling to finish at 39%
No samples have been shared from the other home countries since February 9.
-
Here's the latest variant picture for the United Kingdom, to mid-February.
BA.3.2.* "Cicada" continued to dominate at 72%.
XFG.* "Stratus" continued falling to finish at 25%
Recent samples are only from Northern Ireland.
-
Here's the latest variant picture for the United Kingdom, to mid-February.
BA.3.2.* "Cicada" continued to dominate at 72%.
XFG.* "Stratus" continued falling to finish at 25%
Recent samples are only from Northern Ireland.
-
Here's the latest variant picture for the United Kingdom, to mid-February.
BA.3.2.* "Cicada" continued to dominate at 72%.
XFG.* "Stratus" continued falling to finish at 25%
Recent samples are only from Northern Ireland.
-
Here's the latest variant picture for the United Kingdom, to mid-February.
BA.3.2.* "Cicada" continued to dominate at 72%.
XFG.* "Stratus" continued falling to finish at 25%
Recent samples are only from Northern Ireland.
-
Here's the latest variant picture for the United Kingdom, to mid-February.
BA.3.2.* "Cicada" continued to dominate at 72%.
XFG.* "Stratus" continued falling to finish at 25%
Recent samples are only from Northern Ireland.
-
Here's the latest variant picture for the United Kingdom, to early February.
BA.3.2.* "Cicada" continued its sharp grew suddenly and took over dominance at 44%.
XFG.* "Stratus" continued falling to finish at 32%
-
Here's the latest variant picture for the United Kingdom, to early February.
BA.3.2.* "Cicada" continued its sharp grew suddenly and took over dominance at 44%.
XFG.* "Stratus" continued falling to finish at 32%
-
Here's the latest variant picture for the United Kingdom, to early February.
BA.3.2.* "Cicada" continued its sharp grew suddenly and took over dominance at 44%.
XFG.* "Stratus" continued falling to finish at 32%
-
Here's the latest variant picture for the United Kingdom, to early February.
BA.3.2.* "Cicada" continued its sharp grew suddenly and took over dominance at 44%.
XFG.* "Stratus" continued falling to finish at 32%
-
Here's the latest variant picture for the United Kingdom, to early February.
BA.3.2.* "Cicada" continued its sharp grew suddenly and took over dominance at 44%.
XFG.* "Stratus" continued falling to finish at 32%
-
Here's the latest variant picture for the United Kingdom, to late January.
XFG.* "Stratus" continued falling sharply to finish at 38%
BA.3.2.* grew suddenly and is challenging for dominance at 34%.
-
Here's the latest variant picture for the United Kingdom, to late January.
XFG.* "Stratus" continued falling sharply to finish at 38%
BA.3.2.* grew suddenly and is challenging for dominance at 34%.
-
Here's the latest variant picture for the United Kingdom, to late January.
XFG.* "Stratus" continued falling sharply to finish at 38%
BA.3.2.* grew suddenly and is challenging for dominance at 34%.
-
Here's the latest variant picture for the United Kingdom, to late January.
XFG.* "Stratus" continued falling sharply to finish at 38%
BA.3.2.* grew suddenly and is challenging for dominance at 34%.
-
Here's the latest variant picture for the United Kingdom, to late January.
XFG.* "Stratus" continued falling sharply to finish at 38%
BA.3.2.* grew suddenly and is challenging for dominance at 34%.
-
Here's the latest variant picture for the United Kingdom, to mid-January.
XFG.* "Stratus" remained dominant, but fell sharply to 44%
NB.1.8.1.* "Nimbus" grew steadily to 31%.
BA.3.2.* fell slightly to 20%.
This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.
-
Here's the latest variant picture for the United Kingdom, to mid-January.
XFG.* "Stratus" remained dominant, but fell sharply to 44%
NB.1.8.1.* "Nimbus" grew steadily to 31%.
BA.3.2.* fell slightly to 20%.
This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.
-
Here's the latest variant picture for the United Kingdom, to mid-January.
XFG.* "Stratus" remained dominant, but fell sharply to 44%
NB.1.8.1.* "Nimbus" grew steadily to 31%.
BA.3.2.* fell slightly to 20%.
This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.
-
Here's the latest variant picture for the United Kingdom, to mid-January.
XFG.* "Stratus" remained dominant, but fell sharply to 44%
NB.1.8.1.* "Nimbus" grew steadily to 31%.
BA.3.2.* fell slightly to 20%.
This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.
-
Here's the latest variant picture for the United Kingdom, to mid-January.
XFG.* "Stratus" remained dominant, but fell sharply to 44%
NB.1.8.1.* "Nimbus" grew steadily to 31%.
BA.3.2.* fell slightly to 20%.
This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.
-
Here's the latest variant picture for Europe (excluding the UK), to early January.
BA.3.2.* "Cicada" showed a steady growth advantage of 7% per day (49% per week) over XFG.* "Stratus", with a crossover in late December.
-
Here's the latest variant picture for Europe (excluding the UK), to early January.
BA.3.2.* "Cicada" showed a steady growth advantage of 7% per day (49% per week) over XFG.* "Stratus", with a crossover in late December.
-
Here's the latest variant picture for Europe (excluding the UK), to early January.
BA.3.2.* "Cicada" showed a steady growth advantage of 7% per day (49% per week) over XFG.* "Stratus", with a crossover in late December.
-
Here's the latest variant picture for Europe (excluding the UK), to early January.
BA.3.2.* "Cicada" showed a steady growth advantage of 7% per day (49% per week) over XFG.* "Stratus", with a crossover in late December.
-
Here's the latest variant picture for Europe (excluding the UK), to early January.
BA.3.2.* "Cicada" showed a steady growth advantage of 7% per day (49% per week) over XFG.* "Stratus", with a crossover in late December.
-
Here's the latest variant picture for Australia, to early January.
The overall view is muddied by patchy sequencing volumes. BA.3.2.* "Cicada", NB.1.8.1.* "Nimbus", JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus" all finished in the 22-26% range. This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.
-
Here's the latest variant picture for Australia, to early January.
The overall view is muddied by patchy sequencing volumes. BA.3.2.* "Cicada", NB.1.8.1.* "Nimbus", JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus" all finished in the 22-26% range. This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.
-
Here's the latest variant picture for Australia, to early January.
The overall view is muddied by patchy sequencing volumes. BA.3.2.* "Cicada", NB.1.8.1.* "Nimbus", JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus" all finished in the 22-26% range. This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.
-
Here's the latest variant picture for Australia, to early January.
The overall view is muddied by patchy sequencing volumes. BA.3.2.* "Cicada", NB.1.8.1.* "Nimbus", JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus" all finished in the 22-26% range. This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.
-
Here's the latest variant picture for Australia, to early January.
The overall view is muddied by patchy sequencing volumes. BA.3.2.* "Cicada", NB.1.8.1.* "Nimbus", JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus" all finished in the 22-26% range. This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.